AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Why is Blockchain important to access unpublished data?
Today, blockchain technology applies to a variety of industries. The revolutionary technology that made virtual currency a possibility also enabled hyperledger and smart contracts. This offers an unprecedented opportunity to break down data silos in pharma and access unpublished data.
Unpublished pharma data poses a limitation to successful drug development and increases the chance of another company putting in months of effort, resources on a study that has already been conducted. This is not uncommon in pharma. So, why does this happen so often than not?
90% of clinical trials that fail or are abandoned are considered invaluable, disregarding the important information and findings from various stages. Take for example, Pfizer trials with the antibody bococizumab which showed exciting promise to reduce strokes and heart attacks. However, the trial was abandoned when bococizumab was found to be associated with high-titer anti-drug antibodies, causing health adversity at week 52. The instance of a clinical trial involving close to 27,500 people fail is not that uncommon, however, the news was! While Pfizer published the findings, most companies choose not to disclose failure on account of various reasons.
Failure is the stepping stone to success and these findings can be the key to improve the drug development process in the future. Without publication, a company’s claim to own the data related to that particular clinical trial will be unreliable and thus, the findings even when shared in some other way, cannot be trusted. Even when a company wants to disclose the findings which are negative, they do not get the credit of information or proof of ownership.
Blockchain can solve this problem for the pharmaceutical industry
In a recent Ted Talk, Gunjan Bhardwaj, CEO of Innoplexus Group highlighted the importance of Blockchain in Pharma, by saying:
“Innovation is an iterative and gradual process— new discoveries are built upon previous ones. So, any information that is kept in silos and not accessible holds back innovation.
It is rare for instance to see scientific papers detailing failures of research. Organizations and researchers want a good track record, those funding the research need to show that they are spending wisely, and the editors of journals are mostly interested in putting breakthroughs on their covers. Moreover, even for the information that gets published, the existing peer review process slows down availability dramatically. There can be a delay of 18 or 24 months before research results get published. Meanwhile, often similar studies are being carried out elsewhere, duplicating efforts and increasing costs.
Now, that we are on the verge, thanks to AI, to be able to access, structure and filter all this information, all quality data that has been produced throughout the research ecosystem should be made at least searchable. No technology would be better suited for this than Blockchain… It can secure publishing by establishing authorship through a tamper-proof timestamp, and it can secure sharing through an immutable register of transactions establishing who owns the data and who can access what under what conditions.
Blockchain can finally give researchers the security and trust they need to share even unpublished data.”
Wider access to unpublished pharma data has the power to exponentially improve insights, empowering decision-making, and ultimately reducing the costs and risks of clinical trials.
Featured Blogs
Machine learning as an indispensable tool for Biopharma
The cost of developing a new drug roughly doubles every nine years (inflation-adjusted) aka Eroom’s law.As the volume of data…
Find biological associations between ‘never thought before to be linked’
There was a time when science depended on manual efforts by scientists and researchers. Then, came an avalanche of data…
Find key opinion leaders and influencers to drive your therapy’s
Collaboration with key opinion leaders and influencers becomes crucial at various stages of the drug development chain. When a pharmaceutical…
Impact of AI and Digitalization on R&D in Biopharmaceutical Industry
Data are not the new gold – but the ability to put them together in a relevant and analyzable way…
Why AI Is a Practical Solution for Pharma
Artificial intelligence, or AI, is gaining more attention in the pharma space these days. At one time evoking images from…
How can AI help in Transforming the Drug Development Cycle?
Artificial intelligence (AI) is transforming the pharmaceutical industry with extraordinary innovations that are automating processes at every stage of drug…
How Will AI Disrupt the Pharma Industry?
There is a lot of buzz these days about how artificial intelligence (AI) is going to disrupt the pharmaceutical industry….
Revolutionizing Drug Discovery with AI-Powered Solutions
Drug discovery plays a key role in the pharma and biotech industries. Discovering unmet needs, pinpointing the target, identifying the…
Leveraging the Role of AI for More Successful Clinical Trials
The pharmaceutical industry spends billions on R&D each year. Clinical trials require tremendous amounts of effort, from identifying sites and…
Understanding the Language of Life Sciences
Training algorithms to identify and extract Life Sciences-specific data The English dictionary is full of words and definitions that can be…
Understanding the Computer Vision Technology
The early 1970s introduced the world to the idea of computer vision, a promising technology automating tasks that would otherwise…
AI Is All Hype If We Don’t Have Access to
Summary:AI could potentially speed drug discovery and save time in rejecting treatments that are unlikely to yield worthwhile resultsAI has…